Human metapneumovirus (hMPV) is a respiratory virus that causes infections similar to those caused by respiratory syncytial virus (RSV). First identified in 2001, hMPV affects people of all ages but is most severe in young children, the elderly, and those with weakened immune systems.
hMPV spreads through respiratory droplets when an infected person coughs or sneezes. The virus attaches to cells in the respiratory tract, replicating and causing inflammation. Symptoms typically appear within 5 to 6 days of exposure and can last for 1 to 2 weeks.
hMPV has four main genetic groups (A, B, C, and D), each with subtypes. These groups circulate seasonally, often overlapping with flu and RSV seasons. Unlike influenza, hMPV doesn't undergo significant antigenic shifts, making it less prone to sudden outbreaks.
hMPV is a global pathogen, with outbreaks occurring worldwide, particularly in winter and early spring. It's a leading cause of bronchiolitis and pneumonia in children under 5. In adults, it often manifests as a common cold but can lead to severe lower respiratory tract infections in vulnerable populations.
Many confuse hMPV with RSV or the flu due to similar symptoms. However, hMPV lacks a vaccine, unlike flu and RSV, which have preventive measures. A study published in the Journal of Clinical Virology found that hMPV accounts for about 5-15% of hospitalizations for respiratory infections in children, often misdiagnosed as RSV.
I once treated a patient with persistent cough and fever, initially suspected of having the flu. Testing revealed hMPV, highlighting the importance of accurate diagnosis for proper treatment.
Understanding human metapneumovirus is important for differentiating it from other respiratory illnesses. While it shares symptoms with common cold viruses, its lack of a vaccine and potential severity in certain groups make it a significant public health concern.